| 27.02 -0.71 (-2.56%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.19 | 1-year : | 42.27 |
| Resists | First : | 30.98 | Second : | 36.19 |
| Pivot price | 28.32 |
|||
| Supports | First : | 25.81  |
Second : | 22.62 |
| MAs | MA(5) : | 27.6 |
MA(20) : | 28.43 |
| MA(100) : | 22.63 |
MA(250) : | 18.15 |
|
| MACD | MACD : | 0.8 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 25.7 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 30.98 | Low : | 9.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCAX ] has closed above bottom band by 13.9%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.25 - 28.48 | 28.48 - 28.64 |
| Low: | 26.22 - 26.47 | 26.47 - 26.63 |
| Close: | 26.7 - 27.08 | 27.08 - 27.34 |
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Tue, 14 Jul 2026
Bicara Therapeutics CEO Claire Mazumdar disposes of $284k in stock - Investing.com Nigeria
Tue, 14 Jul 2026
Bicara Therapeutics (BCAX) CEO exercises options and sells 10,000 shares under 10b5-1 plan - Stock Titan
Fri, 10 Jul 2026
Bicara Therapeutics CFO Hyep Ivan sells $807k in stock - Investing.com
Fri, 10 Jul 2026
Bicara Therapeutics (BCAX) CFO sells 28K shares under 10b5-1 plan - Stock Titan
Fri, 10 Jul 2026
Bicara Therapeutics (BCAX) COO exercises options, sells 28,750 shares under plan - Stock Titan
Thu, 02 Jul 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 10,120 (K) |
| Shares Short P.Month | 10,080 (K) |
| EPS | -2.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -32.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -116 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -10.05 |
| PEG Ratio | 0 |
| Price to Book value | 3.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|